IBBETF

The article compares two healthcare sector ETFs: Invesco Pharmaceuticals ETF (PJP), which focuses on 27 pharmaceutical companies, and iShares Biotechnology ETF (IBB), which covers 243 biotech stocks. IBB has a lower expense ratio (0.44% vs 0.58%) and outperformed over the past year (37.7% vs 33.9% return), but PJP offers higher dividend yield (0.92% vs 0.16%) and lower volatility. The choice depends on investor risk tolerance and portfolio goals.

PBE is a smart beta ETF focused on biotechnology and genome companies with $412.99 million in assets. It has delivered strong year-to-date returns of 16.68% and one-year returns of 36.23%, but carries higher risk with a standard deviation of 20.18%.

The fund charges a 0.59% expense ratio and holds concentrated positions in healthcare stocks like Natera, Illumina, and Biogen. Cheaper alternatives like XBI and IBB are available for investors seeking lower-cost options.

The Invesco Biotechnology & Genome ETF (PBE) is a passively managed fund with $418.99 million in assets, offering exposure to the Healthcare-Biotech sector. With a 0.59% expense ratio and 1.38% dividend yield, it returned 18.51% over the past year but carries higher risk with a beta of 0.70 and 20.16% standard deviation.

The fund holds 33 concentrated positions with top holdings including Royalty Pharma, Gilead Sciences, and Biogen. PBE received a Zacks ETF Rank of 3 (Hold), with larger competitors XBI and IBB offering lower expense ratios.

The article compares two healthcare ETFs: IBB (biotech-focused) and IYH (broad healthcare). IBB has delivered stronger 1-year returns (38% vs 17.4%) but exhibits higher volatility and deeper drawdowns. IYH offers lower costs, higher dividend yield, and broader diversification, making it better for most long-term investors, while IBB suits those with conviction in biotech momentum who can tolerate volatility.

The article compares two healthcare ETFs: Vanguard Health Care ETF (VHT) offers broad sector exposure with a low 0.09% expense ratio and 1.4% dividend yield, while iShares Biotechnology ETF (IBB) focuses on biotech with higher growth potential (49.8% 1-year return) but greater volatility and a 39.8% maximum drawdown. VHT is recommended for conservative investors seeking stability, while IBB suits high-risk growth investors.

The October 14 CPI report will determine Social Security's 2027 COLA, which is projected to be around 3.5% based on July and August CPI-W data. This would increase the average retired worker's monthly benefit from $2,088 to approximately $2,161, an increase of $73 per month. However, critics argue CPI-W doesn't fully capture retirees' actual inflation costs, particularly healthcare.